AbCellera Biologics Inc. [NASDAQ: ABCL] loss -13.56% on the last trading session, reaching $31.37 price per share at the time. The company report on March 10, 2021 that AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19.
Patients who received bamlanivimab and etesevimab together had an 87% reduction in hospitalizations and death; no patients died who received the therapy.
AbCellera (Nasdaq: ABCL) announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19. These results mark the second positive Phase 3 trial readout for bamlanivimab and etesevimab together, adding to the growing safety and efficacy data that has resulted in the following key milestones accelerating the adoption of the antibody therapy globally:.
AbCellera Biologics Inc. represents 261.64 million in outstanding shares, while the company has a total market value of $8.21 billion with the latest information. ABCL stock price has been found in the range of $30.7501 to $36.15.
If compared to the average trading volume of 934.19K shares, ABCL reached a trading volume of 1086068 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about AbCellera Biologics Inc. [ABCL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABCL shares is $55.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABCL stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
SVB Leerink have made an estimate for AbCellera Biologics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 05, 2021. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on January 05, 2021, representing the official price target for AbCellera Biologics Inc. stock. Previously, the target price had yet another raise to $52, while Credit Suisse analysts kept a Outperform rating on ABCL stock.
The Average True Range (ATR) for AbCellera Biologics Inc. is set at 3.60, with the Price to Sales ratio for ABCL stock in the period of the last 12 months amounting to 402.34.
Trading performance analysis for ABCL stock
AbCellera Biologics Inc. [ABCL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -12.86.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABCL stock in for the last two-week period is set at 37.88, with the RSI for the last a single of trading hit 36.73, and the three-weeks RSI is set at 38.08 for AbCellera Biologics Inc. [ABCL]. The present Moving Average for the last 50 days of trading for this stock 41.97, while it was recorded at 35.93 for the last single week of trading.
AbCellera Biologics Inc. [ABCL]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and AbCellera Biologics Inc. [ABCL] shares currently have an operating margin of -35.46. AbCellera Biologics Inc.’s Net Margin is presently recorded at -19.04.
Return on Total Capital for ABCL is now -26.23, given the latest momentum, and Return on Invested Capital for the company is -16.51. Return on Equity for this stock declined to -20.22, with Return on Assets sitting at -9.83. When it comes to the capital structure of this company, AbCellera Biologics Inc. [ABCL] has a Total Debt to Total Equity ratio set at 59.35. Additionally, ABCL Total Debt to Total Capital is recorded at 37.24, with Total Debt to Total Assets ending up at 25.91. Long-Term Debt to Equity for the company is recorded at 147.98, with the Long-Term Debt to Total Capital now at 24.51.
Reflecting on the efficiency of the workforce at the company, AbCellera Biologics Inc. [ABCL] managed to generate an average of -$20,661 per employee. Receivables Turnover for the company is 4.96 with a Total Asset Turnover recorded at a value of 0.52.AbCellera Biologics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.60 and a Current Ratio set at 5.70.
An analysis of insider ownership at AbCellera Biologics Inc. [ABCL]
There are presently around $2,136 million, or 38.10% of ABCL stock, in the hands of institutional investors. The top three institutional holders of ABCL stocks are: VIKING GLOBAL INVESTORS LP with ownership of 19,283,744, which is approximately New of the company’s market cap and around 23.40% of the total institutional ownership; BAKER BROS. ADVISORS LP, holding 10,450,180 shares of the stock with an approximate value of $327.82 million in ABCL stocks shares; and ORBIMED ADVISORS LLC, currently with $263.53 million in ABCL stock with ownership of nearly New of the company’s market capitalization.
Positions in AbCellera Biologics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 61 institutional holders increased their position in AbCellera Biologics Inc. [NASDAQ:ABCL] by around 68,103,702 shares. Additionally, 0 investors decreased positions by around 0 shares, while 0 investors held positions by with 0 shares. The mentioned changes placed institutional holdings at 68,103,702 shares, according to the latest SEC report filing. ABCL stock had 61 new institutional investments in for a total of 68,103,702 shares, while 0 institutional investors sold positions of 0 shares during the same period.